Drug Profile
Research programme: liver cell transplant therapy - Vesta Therapeutics
Alternative Names: Progenitor liver cell transplant therapy - Vesta TherapeuticsLatest Information Update: 26 Apr 2012
Price :
$50
*
At a glance
- Originator Vesta Therapeutics
- Developer Clinical Data; Vesta Therapeutics
- Class Cell therapies
- Mechanism of Action Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Liver disorders
Most Recent Events
- 26 Apr 2012 No development reported - Preclinical for Liver disorders in USA (IV)
- 13 Apr 2011 Clinical Data has been acquired by Forest Laboratories
- 25 Jan 2007 Preclinical development is ongoing